Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialLancet - Heijerman, HG M; McKone, E F; Downey, D G (2019)
et al.